Abcuro, a Newton, MA-based clinical-stage biotechnology company, raised $200M in Series C funding.
The round was led by New Enterprise Associates (NEA) joined by Foresite Capital with participation from existing investors including RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, abrdn Inc., BlackRock, Eurofarma Ventures, and Soleus Capital.
The company intends to use the funds to complete the registrational Phase 2/3 MUSCLE clinical trial evaluating ulviprubart (ABC008), a monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of inclusion body myositis (IBM).
Led by CEO Alex Martin, Abcuro is a clinical stage biotechnology company developing immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. Its lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.
FinSMEs
13/02/2025